Edward Barias, MD
Addiction Psychiatry · Jupiter, FLNPI 1689007700
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,086 of the $20,793 with a category attached, or 87.0%. 32 manufacturers reported payments, led by AbbVie at 30.6% of the total. Among addiction psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 868 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- plus $7K from 26 others
What the payments were for
- Speaking & faculty fees$2,62513%
- Food & beverage$18,08687%
- Education$820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 212 | $6,357 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,859 |
| Alkermes, Inc. | 71 | $1,569 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 92 | $1,294 |
| Johnson & Johnson | 54 | $1,140 |
| Neurocrine Biosciences, Inc. | 39 | $1,105 |
| Corium, LLC | 29 | $709 |
| Teva Pharmaceuticals USA, Inc. | 34 | $675 |
| Lundbeck LLC | 39 | $595 |
| Indivior Inc. | 22 | $565 |
| Axsome Therapeutics, Inc. | 15 | $429 |
| Livanova USA, Inc. | 9 | $381 |
| Sunovion Pharmaceuticals Inc. | 20 | $373 |
| Eisai Inc. | 6 | $313 |
| Vanda Pharmaceuticals Inc. | 15 | $294 |
| E.r. Squibb & Sons, L.L.C. | 15 | $270 |
| Tris Pharma Inc | 10 | $204 |
| Idorsia Pharmaceuticals US Inc | 10 | $198 |
| Bausch Health US, LLC | 10 | $176 |
| Supernus Pharmaceuticals, Inc. | 8 | $166 |
| Almatica Pharma LLC | 7 | $149 |
| Braeburn Inc. | 5 | $125 |
| Alfasigma USA, Inc. | 5 | $114 |
| Noven Therapeutics, LLC | 2 | $47 |
| Neuronetics, Inc. | 2 | $41 |
| Merck | 2 | $28 |
| Biogen | 1 | $27 |
| Brainsway USA Inc | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,793 in reported general payments places this provider in the 90th percentile of 29 addiction psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 34 | $94,566 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,891 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $7,854 |
| Aripiprazole | 70 | $4,858 |
| Quetiapine Fumarate | 111 | $2,279 |
| Clonazepam | 259 | $2,130 |
| Clozapine | 38 | $2,042 |
| Duloxetine Hcl | 73 | $1,843 |
| Lamotrigine | 112 | $1,774 |
| Trazodone Hcl | 91 | $1,604 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 49 | $1,538 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,406 |
| Bupropion XlBupropion Hcl | 91 | $1,352 |
| Vilazodone Hcl | 16 | $1,294 |
| Mirtazapine | 82 | $1,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,859 | $94,56634 claims |
| Johnson & JohnsonInvega Sustenna | $1,140 | $27,89112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,294 | $7,85413 claims |
| Almatica Pharma LLCSertraline Hcl | $149 | $37666 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 29 addiction psychiatry providers in Florida.
Other addiction psychiatry in Jupiter
- Raul RodriguezDelray Beach$31K
- Jason FieldsNew Port Richey$26K
- Mary SheehanTampa$16K
- Aldo MoralesFort Lauderdale$13K
- Krishan BatraOdessa$10K
- Lawrence WeinsteinSt Petersburg$6K
- Syed ZaidiPinellas Park$5K
- Vincence DillonPensacola$2K
- Curtis PhillipsDelray Beach$2K
- Zaheer AslamFort Myers$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.